Yale study reveals insights into post-vaccine heart inflammation cases

In a new study, Yale scientists have identified the immune signature of rare cases of myocarditis among those vaccinated against COVID-19 with mRNA vaccines.
Human heart illustration

(© stock.adobe.com)

When new COVID-19 vaccines were first administered two years ago, public health officials found an increase in cases of myocarditis, an inflammation of the heart muscle, particularly among young males who had been vaccinated with mRNA vaccines. It was unclear, however, what exactly was causing this reaction.

In a new study, Yale scientists have identified the immune signature of these heart inflammation cases.

These findings, published May 5 in the journal Science Immunology, rule out some of the theorized causes of the heart inflammation and suggest potential ways to further reduce the incidence of a still rare side effect of vaccination, the authors say.

Myocarditis is a generally mild inflammation of heart tissue which can cause scarring but is usually resolved within days. The increased incidence of myocarditis during vaccination was seen primarily in males in their teens or early 20s, who had been vaccinated with mRNA vaccines, which are designed to elicit immune responses specifically to the SARS-CoV-2 virus.

According to the Centers for Disease Control and Prevention (CDC), among males aged 12 to 17, about 22 to 36 per 100,000 experienced myocarditis within 21 days after receiving a second vaccine dose. The incidence of myocarditis was 50.1 to 64.9 cases per 100,000 after infection with the COVID-19 virus among males in this age group.

For the new study, the Yale research team conducted a detailed analysis of immune system responses in those rare cases of myocarditis among vaccinated individuals. The team was led by Carrie Lucas, associate professor of immunobiology, Akiko Iwasaki, Sterling Professor of Immunobiology, and Inci Yildirim, associate professor of pediatrics and epidemiology.

They found that the heart inflammation was not caused by antibodies created by the vaccine, but rather by a more generalized response involving immune cells and inflammation.

The immune systems of these individuals get a little too revved up and over-produce cytokine and cellular responses,” Lucas said.

Earlier research had suggested that increasing the time between vaccination shots from four to eight weeks may  reduce risk of developing myocarditis.

Lucas noted that, according to CDC findings, the risk of severe forms of myocarditis is greater in individuals who contract the COVID-19 virus than in those who receive vaccines. She emphasized that vaccination offers the best protection from COVID-19-related disease.

I hope this new knowledge will enable further optimizing mRNA vaccines, which, in addition to offering clear health benefits during the pandemic, have a tremendous potential to save lives across numerous future applications,” said Anis Barmada, an M.D./Ph.D. student at Yale School of Medicine, who is a co-first author of the paper with Jon Klein, also a Yale M.D./Ph.D. student.

Share this with Facebook Share this with X Share this with LinkedIn Share this with Email Print this
Part of the In Focus Collection: Yale responds to COVID-19

Media Contact

Bess Connolly : elizabeth.connolly@yale.edu,